Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Seeks Feedback On Home Dialysis Training Costs In 2014 Draft ESRD Payment Policy

This article was originally published in The Gray Sheet

Executive Summary

Following through on its commitment to continue analyzing trends in home dialysis training, CMS is requesting comments in the 2014 end-stage renal disease prospective payment system proposed rule on the costs associated with furnishing self-dialysis or home dialysis training.

You may also be interested in...



CMS Softens End-Stage Renal Disease Cuts, Increases Pay For Home Dialysis

Despite offsets and a ruling by CMS to phase-in rather than immediately implement end-stage renal disease bundled payment cuts, stakeholders say the recently finalized 2014 Medicare reimbursement policy for ESRD is not sufficient.

ESRD Stakeholders Reiterate Request For More Pay For Home Dialysis Training

In comments on the costs associated with furnishing self-dialysis or home dialysis training, dialysis equipment manufacturers and other ESRD stakeholders echoed previous requests that CMS set payment rates that reflect the actual time and cost of providing such services.

Reimbursement Briefs: Opposition To Dialysis Cuts; OIG On Prosthetics; AHA On Quality Measures

Dialysis groups react to end-stage renal disease prospective payment system proposed rule. Medicare administrative contractor CGS paid unallowable claims for lower-limb prosthetics. AHA weighs in on potential cancer hospital quality measures

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel